Biotech IV Monitor

NVCR — NovoCure Limited

$2.1B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for NovoCure Limited, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is October 2028.

Next readoutOctober 2028in ~23 months
Upcoming readouts22 Phase 3
Market cap$2.1B
Cash & investments$97M~9 quarters at last loss rate
Recent 8-K filings2latest 2026-11-09

Upcoming readouts

Phase 3 NovoTTF-200T
Metastatic Non-small Cell Lung Cancer · NCT06216301
October 2028
Recruiting
Phase 3 Optune® device
Glioblastoma · NCT06556563
April 2029
Ongoing

Cash position

NovoCure Limited reported $97M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $10M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-09
8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow NVCR, you can start the conversation.
Track NVCR in real time
See live implied volatility for NVCR and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on NVCR
Contact — questions or corrections about NVCR: dukeupt@gmail.com